(Updated - May 8, 2018 4:36 PM EDT)

Prothena Corp. (NASDAQ: PRTA) reported Q1 EPS of ($1.26), $0.73 worse than the analyst estimate.

• Net cash used in operating and investing activities was $31.8 million in the first quarter; quarter-end cash and restricted cash position of $433.1 million supports advancement through key milestones of R&D pipeline
• Entered into global neuroscience research & development collaboration with Celgene to advance novel therapies for patients with neurodegenerative diseases
• Initiated a first-in-human study of PRX004 in patients with ATTR amyloidosis

For earnings history and earnings-related data on Prothena Corp. (PRTA) click here.

Earnings Guidance